Health Score

0 Fair

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Deposit reference lists for 229 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact229 DOIs

Add license metadata to 128 records

License metadata tells indexers and readers how each article may be reused.

High impact128 DOIs

Attach ORCID iDs across 27 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact27 DOIs

DOIs for this ISSN

Showing the top 5 of 229 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Rola dodatkowych ubezpieczeń zdrowotnych nowego typu (ubezpi… (10.7365/jhpor.2012.1.18)	Abstract References ORCID License	47.71	2
2	Pharmaceutical Policies under Economic Crisis: The Greek cas… (10.7365/jhpor.2016.2.1)	References License	45.15	7
3	Multi-criteria decision analysis (MCDA) and its alternatives… (10.7365/jhpor.2015.1.4)	References License	34.95	4
4	Adoption of Real World Evidence in decision-making processes… (10.7365/jhpor.2015.2.3)	References License	34.95	4
5	Economic Burden of Healthcare Utilisation by Older Persons L… (10.7365/jhpor.2024.1.1)	References License	34.95	4
6	The Devastating Impact of Toxic Leadership on Health-Care Or… (10.7365/jhpor.2024.1.8)	Abstract References	34.95	4
7	Therapeutic proteins: facing the challenges of glycobiology (10.7365/jhpor.2014.5.2)	Abstract References ORCID License	30.10	1
8	Treatment options in chronic lymphocytic leukemia (CLL) – a… (10.7365/jhpor.2018.1.3)	References License	30.10	3
9	Aging society: organization of long-term care for the elderl… (10.7365/jhpor.2018.1.5)	References License	30.10	3
10	Indirect costs of pneumococcal diseases in Poland: estimatio… (10.7365/jhpor.2019.2.2)	References License	30.10	3
11	Cost per Responder Analysis of Biologics in Moderate-to-seve… (10.7365/jhpor.2021.1.2)	References License	30.10	3
12	A study of various existing interventions for the treatment… (10.7365/jhpor.2022.1.4)	References License	30.10	3
13	Indicators affecting the quality of life of an individual an… (10.7365/jhpor.2023.1.2)	References	26.98	11
14	Cost effectiveness of the fixed combination of indacaterol/g… (10.7365/jhpor.2015.1.6)	References License	23.86	2
15	Pharmaceutical system in Ukraine: current and prospective is… (10.7365/jhpor.2015.2.8)	References License	23.86	2
16	Assessment of Quality of life (QoL) in postmenopausal osteop… (10.7365/jhpor.2016.1.11)	References License	23.86	2
17	The combination of angiotensin converting enzyme inhibitors,… (10.7365/jhpor.2018.1.2)	References License	23.86	2
18	The cost of macro- and microvascular diseases in patients wi… (10.7365/jhpor.2019.1.5)	References License	23.86	2
19	Shifting towards Value Based Healthcare – Analysis of theore… (10.7365/jhpor.2021.1.3)	References License	23.86	2
20	Readiness of the health system against COVID-19 and its impa… (10.7365/jhpor.2023.2.1)	References License	23.86	2
21	Drug policy as an integral part of state health policy - int… (10.7365/jhpor.2017.1.1)	References ORCID License	22.58	1
22	Early medical technology assessments of medical devices and… (10.7365/jhpor.2013.3.2)	References ORCID	15.05	1
23	Availability of pneumococcal vaccination programmes in Europ… (10.7365/jhpor.2013.3.3)	References	15.05	3
24	The overview of Agency for Health Technology Assessment reco… (10.7365/jhpor.2014.2.2)	References ORCID	15.05	1
25	Telemedicine - a challenge rather than solution for payers a… (10.7365/jhpor.2015.1.1)	References ORCID	15.05	1
26	The evolving landscape for Real World Evidence in Poland: ph… (10.7365/jhpor.2015.1.3)	References License	15.05	1
27	Real-life treatment patterns and medication costs in patient… (10.7365/jhpor.2015.2.4)	References License	15.05	1
28	Assessment of quality and clinical significance of endpoints… (10.7365/jhpor.2015.2.5)	References License	15.05	1
29	The problem of thresholds determination in ranking classifie… (10.7365/jhpor.2016.1.4)	References License	15.05	1
30	The assessment of the impact of thrombocytopenia symptoms on… (10.7365/jhpor.2016.1.6)	References License	15.05	1
31	Thrombocytopenia Symptoms and their Impact on Patients Daily… (10.7365/jhpor.2016.1.7)	References License	15.05	1
32	Diabetic Macular Edema treatment limits in Poland (10.7365/jhpor.2016.1.8)	References License	15.05	1
33	Healthcare needs maps – evidence informed healthcare policy (10.7365/jhpor.2017.1.2)	References License	15.05	1
34	Visualisation of the results of sequence analysis with the u… (10.7365/jhpor.2017.1.4)	References License	15.05	1
35	Reimbursement and value assessment frameworks: ensuring pati… (10.7365/jhpor.2017.1.5)	References License	15.05	1
36	To assess the perceived burnout symptoms and coping strategi… (10.7365/jhpor.2017.1.6)	References License	15.05	1
37	Cost-utility analysis and budget impact analysis of pegvisom… (10.7365/jhpor.2018.2.3)	References License	15.05	1
38	Secondary immunodeficiencies – do we need systemic solutions… (10.7365/jhpor.2019.1.1)	References License	15.05	1
39	Supporting role of non-governmental health insurance schemes… (10.7365/jhpor.2020.1.4)	References License	15.05	1
40	Challenges and opportunities in the treatment of chronic rhi… (10.7365/jhpor.2021.2.4)	References License	15.05	1
41	Comparative analysis of the understanding the "ten-star phar… (10.7365/jhpor.2022.2.1)	References License	15.05	1
42	Contact Tracing /Filiation Cost for COVID-19 in Türkiye (10.7365/jhpor.2022.2.3)	References License	15.05	1
43	COVID-19 SEVERITY AND MORTALITY RATE AMONG PEOPLE IN NORTHWE… (10.7365/jhpor.2022.2.5)	References License	15.05	1
44	Social/ economic burden and health-related quality of life i… (10.7365/jhpor.2023.2.6)	References License	15.05	1
45	The value of the health care transition in the treatment of… (10.7365/jhpor.2023.2.7)	References License	15.05	1
46	The organization of the health care system in the Russian Fe… (10.7365/jhpor.2012.1.16)	References	11.93	2
47	Stage III/IV Melanoma in Poland: epidemiology, standard of c… (10.7365/jhpor.2012.1.21)	References	11.93	2
48	Mammography screening in the OECD and its impact on health a… (10.7365/jhpor.2014.5.9)	References	11.93	2
49	Real world data guidelines - current status review (10.7365/jhpor.2015.1.2)	References	11.93	2
50	Advancements in diabetes Care in Poland (10.7365/jhpor.2023.1.6)	References	11.93	2